Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 Meeting Abstract
| Authors: | Modi, S.; Niikura, N.; Yamashita, T.; Jacot, W.; Sohn, J.; Tokunaga, E.; Vidal, M. J.; Park, Y. H.; Lee, K. S.; Chae, Y.; Ueno, N.; Prat, A.; Suto, F.; Kuwahara, Y.; McEwen, R.; Feng, W.; Goto, H.; Orbegoso, C.; Cameron, D. A.; Tsurutani, J. |
| Abstract Title: | Trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low, hormone receptor-positive (HR+) unresectable and/or metastatic breast cancer (mBC): Exploratory biomarker analysis of DESTINY-Breast04 |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.1020 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 1020 -- This meeting was also held virtually -- Source: Cinahl |
